Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 9/20 | 0.55 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31737693 | 0.91 | UTS2R (0.46) | SMYD3UTS2RMCHR1ACKR3KDM4E | |
| SCHEMBL4970792 | 0.89 | MCHR1 (0.55) | SMYD3UTS2RMCHR1KDM4E | |
| SCHEMBL28264042 | 0.84 | RAB9A (0.52) | MCHR1 | |
| SCHEMBL2554945 | 0.84 | RAB9A (0.52) | MCHR1 | |
| SCHEMBL27124836 | 0.82 | MCHR1 (0.50) | UTS2RMCHR1KDM4E | |
| SCHEMBL29745057 | 0.76 | GRM5 (0.67) | SMYD3UTS2RKDM4E | |
| Hydrochloric Acid SCHEMBL28155973 | 0.75 | GRM5 (0.65) | SMYD3UTS2RKDM4E | |
| Hydrochloric Acid SCHEMBL4713340 | 0.75 | GRM5 (0.65) | SMYD3UTS2RKDM4E | |
| SCHEMBL17396263 | 0.74 | SMYD3 (0.52) | SMYD3ACKR3EPHX1POLBHPGDS | |
| SCHEMBL28184168 | 0.73 | KDM4E (0.42) | UTS2RKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242565-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF IN THE PREVENTION OR THERAPY OF DISEASES | Samsara Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| CN-105744833-B | Use the fluidized bed prilling of Prohexadione calcium and the aqueous solution of mineral sulfates | 巴斯夫欧洲公司 | 2018-07-24 | — | — | CN | disclosed |
| CN-103561570-B | Alkoxylated polyalkyleneimine as agrochemical formula dispersant | 巴斯夫欧洲公司 | 2016-10-05 | — | — | CN | disclosed |
| CN-104378980-B | Comprise the emulsifiable concentrate of pesticide, amide, carbonic ester and hydrocarbon | 巴斯夫欧洲公司 | 2016-08-24 | — | — | CN | disclosed |
| US-8106048-B2 | protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester | 4SC AG (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2343293-A1 | NOVEL PIPERIDIN-4-YL-THIAZOLE-CARBOXAMIDE ANALOGUES AS INHIBITORS OF T-CELL PROLIFERATION AND USES THEREOF | 4SC AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-20110052532-A1 | Pharmaceutical composition comprising a cytokine | STROBL STEFAN | 2011-03-03 | — | — | US | disclosed |
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-7812041-B2 | Heterocyclic NF-κB inhibitors | 4SC AG (DE) | 2010-10-12 | — | — | US | disclosed |
| WO-2007104558-A1 | THIAZOLES AS NF-KB INHIBITORS (PROTEASOME INHIBITORS) | 4SC AG (DE) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104557-A2 | NOVEL HETEROCYCLIC NF-KB INHIBITORS | 4SC AG (DE) | 2007-09-20 | — | — | WO | disclosed |
| US-20070219190-A1 | Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2007-09-20 | — | — | US | disclosed |
| EP-1834954-A1 | Thiazoles as NF-kB Inhibitors (proteasome inhibitors) | 4SC AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| EP-1797084-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007016979-A2 | NOVEL HETEROCYCLIC NF-κB INHIBITORS | 4SC AG (DE) | 2007-02-15 | — | — | WO | disclosed |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-11-02 | — | — | US | disclosed |
| WO-2006032322-A1 | NOVEL HETEROCYCLIC NF-κB INHIBITORS | 4SC AG (DE) | 2006-03-30 | — | — | WO | disclosed |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-03-30 | — | — | US | disclosed |
| EP-1637529-A1 | Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof | 4SC AG (DE) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | SMYD3 1714/4885UTS2R 836/4885MCHR1 3580/4885 |
| US-20110052532-A1 | Pharmaceutical composition comprising a cytokine | IL2, IL17A, IFNG | SMYD3 4868/4885UTS2R 4380/4885MCHR1 814/4885 |
| US-20070219190-A1 | Heterocyclic NF-kB Inhibitors | NFKBIA, NFKB2, NFRKB | SMYD3 2428/4885UTS2R 1517/4885MCHR1 3063/4885 |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFRKB, NFKB2 | SMYD3 2968/4885UTS2R 2096/4885MCHR1 3308/4885 |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKB2, NFKBIA, NFRKB | SMYD3 1714/4885UTS2R 836/4885MCHR1 3580/4885 |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFKB2, NFRKB | SMYD3 2305/4885UTS2R 1436/4885MCHR1 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.